Cover Image
市場調查報告書

RAPID Pharmaceuticals AG的產品平台分析

RAPID Pharmaceuticals AG - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 320922
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
RAPID Pharmaceuticals AG的產品平台分析 RAPID Pharmaceuticals AG - Product Pipeline Review - 2014
出版日期: 2014年12月10日 內容資訊: 英文 22 Pages
簡介

RAPID Pharmaceuticals AG是總公司設立於瑞士的生物製藥企業,正在開發·製造針對感染疾病、神經退化性疾病、發炎疾病的勝肽醫藥品。提供進行性多灶性白質腦病、免疫重組症候群、多發性硬化症、老年癡呆症、自閉症光譜、輕度創傷性腦損傷、神經病變造成的疼痛、糖尿病神經病變等治療藥。

本報告提供RAPID Pharmaceuticals AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

RAPID Pharmaceuticals AG的基本資料

  • RAPID Pharmaceuticals AG概要
  • 主要資訊
  • 企業資料

RAPID Pharmaceuticals AG:R&D概要

  • 主要的治療範圍

RAPID Pharmaceuticals AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

RAPID Pharmaceuticals AG:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

RAPID Pharmaceuticals AG:藥物簡介

  • RAP-102
  • RAP-103
  • RAP-310
  • RAP-701

RAPID Pharmaceuticals AG:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

RAPID Pharmaceuticals AG:開發暫停中的計劃

RAPID Pharmaceuticals AG:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

目錄
Product Code: GMDHC06632CDB

Summary

Global Markets Direct's, 'RAPID Pharmaceuticals AG - Product Pipeline Review - 2014', provides an overview of the RAPID Pharmaceuticals AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of RAPID Pharmaceuticals AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of RAPID Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of RAPID Pharmaceuticals AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the RAPID Pharmaceuticals AG's pipeline products

Reasons to buy

  • Evaluate RAPID Pharmaceuticals AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of RAPID Pharmaceuticals AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the RAPID Pharmaceuticals AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of RAPID Pharmaceuticals AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of RAPID Pharmaceuticals AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of RAPID Pharmaceuticals AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RAPID Pharmaceuticals AG Snapshot
    • RAPID Pharmaceuticals AG Overview
    • Key Information
    • Key Facts
  • RAPID Pharmaceuticals AG - Research and Development Overview
    • Key Therapeutic Areas
  • RAPID Pharmaceuticals AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • RAPID Pharmaceuticals AG - Pipeline Products Glance
    • RAPID Pharmaceuticals AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • RAPID Pharmaceuticals AG - Drug Profiles
    • RAP-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RAP-103
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RAP-310
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RAP-701
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RAPID Pharmaceuticals AG - Pipeline Analysis
    • RAPID Pharmaceuticals AG - Pipeline Products by Target
    • RAPID Pharmaceuticals AG - Pipeline Products by Route of Administration
    • RAPID Pharmaceuticals AG - Pipeline Products by Molecule Type
    • RAPID Pharmaceuticals AG - Pipeline Products by Mechanism of Action
  • RAPID Pharmaceuticals AG - Dormant Projects
  • RAPID Pharmaceuticals AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RAPID Pharmaceuticals AG, Key Information
  • RAPID Pharmaceuticals AG, Key Facts
  • RAPID Pharmaceuticals AG - Pipeline by Indication, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Stage of Development, 2014
  • RAPID Pharmaceuticals AG - Monotherapy Products in Pipeline, 2014
  • RAPID Pharmaceuticals AG - Preclinical, 2014
  • RAPID Pharmaceuticals AG - Discovery, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Target, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Route of Administration, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Molecule Type, 2014
  • RAPID Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2014
  • RAPID Pharmaceuticals AG - Dormant Developmental Projects,2014
  • RAPID Pharmaceuticals AG, Subsidiaries

List of Figures

  • RAPID Pharmaceuticals AG - Pipeline by Top 10 Indication, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Stage of Development, 2014
  • RAPID Pharmaceuticals AG - Monotherapy Products in Pipeline, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Top 10 Target, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Top 10 Route of Administration, 2014
  • RAPID Pharmaceuticals AG - Pipeline by Top 10 Molecule Type, 2014
  • RAPID Pharmaceuticals AG - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top